resectable pancreatic cancer
Conditions
Interventions
Gemcitabine(1000mg/m2) is given by intravenous infusion over 30 min on day1, 8. S-1(65mg/m2) is given oral for 14 days followed by a 1-week rest. This cycle was repeated twice.
Sponsors
Tokai university, school of medicine
Tokai University Hachioji Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)resectable or borderline resectable pancreatic cancer 2)sytologically or histrogically proven pancreatic invasive ductal cancer 3)all adult who anticipate to undergo pancreatectomy 4)Eastern Cooperative Oncology Group performance status of 0-1 5)adequate oral intake 6)adequate organ function 7)written informed consent
Exclusion criteria
Exclusion criteria: 1)pulmonary fibrosis or interstitional pneumonaitis 2)prior anti-cancer therapy(chemotherapy,radiation therapy ,chemoradiation therapy) 3)active infection 4)syncronous cancers 5)severe complication 6)severe mental disorder 7)watery diarrhea 8)pregnancy 9)iodine allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resection rate | — |
Secondary
| Measure | Time frame |
|---|---|
| resection rate, adverse effect, completion rate, recurrence free survival, two-year survival rate, pathological effect | — |
Countries
Japan
Outcome results
None listed